Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PRNP | P04156 | 1/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8768170 | 0.87 | ADRA2A (0.48) | SMN1; SMN2ADRA2AMTNR1AMTNR1BCA1 | |
| SCHEMBL346945 | 0.86 | ADRA2A (0.48) | SMN1; SMN2ADRA2AMTNR1AMTNR1BCA1 | |
| SCHEMBL345064 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL345524 | 0.84 | SOD1 (0.48) | SMN1; SMN2CA1CA2ACHE | |
| SCHEMBL3307587 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2ADRA2AMTNR1AMTNR1BCA1 | |
| SCHEMBL30834270 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2ADRA2ANPC1POLBRAB9A | |
| SCHEMBL19469587 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ADRA2AMTNR1AMTNR1BKDM1A | |
| SCHEMBL20584777 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2ADRA2ANPC1POLBRAB9A | |
| SCHEMBL19469584 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ADRA2AMTNR1AMTNR1BKDM1A | |
| SCHEMBL19469633 | 0.78 | SMN1; SMN2 (0.69) | SMN1; SMN2ADRA2AMTNR1AMTNR1BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | SMN1; SMN2 567/4885ADRA2A 1340/4885MTNR1A 1579/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | SMN1; SMN2 1515/4885ADRA2A 642/4885MTNR1A 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.